ESMO25: Immuno-therapies and translational research in oncol...

Dr Inge Marie Svane – Professor in Clinical cancer immune therapy and director of the translational research centre, CCIT, on IO Biotech's ESMO25 data

ESMO25: The changing landscape of rare oncology, with Jan Ki...

ESMO sees many presentations on cancers of the lung, breast, and bladder - for example - but this year there was meaningful data in rare cancers, too.

On targeted radiotherapeutics, with Marc Hedrick

Dr Marc Hedrick, president and CEO of Plus Therapeutics, discusses developing targeted radiotherapeutics.

Advances in breast cancer: What’s new from ESMO 2025

ESMO 2025 showcased the breadth and urgency of breast cancer research, which remains one of the most diagnosed malignancies worldwide.

ESMO25: Following the science to a cure, with Nancy Ghattas

ESMO25: Acceleration, accessibility, and accuracy, with Barr...

At ESMO25, pharmaphorum spoke with Barry Vucsko, Senior VP of Strategic Development, Agency Services, for the EVERSANA Oncology Centre of Excellence.